Conjunctivitis has been a known adverse event in patients taking dupilumab to treat atopic dermatitis (AD). Data was analyzed to explore practical predictors of later development of conjunctivitis in patients with AD on dupilumab.
Learn more at the Journal of the American Academy of Dermatology.